About Hyku Biosciences
Hyku Biosciences is a private company based in Concord, Massachusetts. It has reported $15,212,446 raised in two offerings on Form D since January 2026. Its chief executive is Kleem Chaudhary.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Aug 13, 2026 | $8,612,446fully sold | 4 | $2.1M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 10, 2025 | Jan 2, 2026 | $6,600,000of $21.0M target | 8 | $825K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $15,212,446 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Hyku Biosciences's Form D filed Aug 13, 2026.
JG
John Gustofson
President and director
MW
Matthias Van Woensel
Partner and director
KC
JN
Janwillem Naesens
Managing Partner Oncology &, director
Earlier filings also listed Laura Tadvalkar (director, last listed Jan 2026) and Laura Brass (director, last listed Jan 2026).